search
Back to results

A Study for Leukemia Patients With Life-Threatening Infections

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
White Blood Cell Transfusion
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring White Blood Cell Transfusion, Radiated Cells, Unradiated Cells, Leukocyte Transfusions, Life-threatening Infections

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosis of hematologic malignancy admitted to the Leukemia service.
  2. Severe neutropenia defined as Absolute neutrophil count (ANC) less than or equal to 1000.
  3. Persistent fever and/or signs of life threatening infection despite 48 hours on antibiotics.
  4. Sign a written informed consent form.
  5. Greater than 18 years of age.

Exclusion Criteria:

1) None

Sites / Locations

  • UT MD Anderson Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Non-radiated White Blood Cell Transfusion

White Blood Cell Transfusion

Arm Description

Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.

Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.

Outcomes

Primary Outcome Measures

Number of Participants Alive at Day 30
Participant survival measured over the 30 days subsequent to the first granulocyte transfusion. Collecting complete blood counts (CBCs) pre and post transfusion allows determination of whether the duration of neutrophil replacement differs between the two study groups (comparing unradiated white blood cells to radiated white blood cell infusion).

Secondary Outcome Measures

Full Information

First Posted
August 27, 2009
Last Updated
November 1, 2013
Sponsor
M.D. Anderson Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00968838
Brief Title
A Study for Leukemia Patients With Life-Threatening Infections
Official Title
Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical research study is to compare the effectiveness of a white blood cell transfusion with radiated cells to a white blood cell transfusion with cells that have not been radiated. The safety of this procedure will also be studied.
Detailed Description
Radiated White Blood Cell Transfusions: White blood cell transfusions from a volunteer donor may contain blood cells that your body can react with to produce a disorder called transfusion-associated graft versus host disease. This means that some of the injected white blood cells can reproduce in your body and react with your own tissues and create side effects. To avoid this, the blood is radiated (changed through radiation) to kill all the cells that can divide. But this radiation also may destroy some of the infection-fighting capacity of the white blood cell transfusion, this may decrease the effectiveness of these white blood cell transfusions. Radiating white blood cells is the standard procedure that has been used to treat serious, life-threatening infections. Non-Radiated White Blood Cell Transfusions: If the white blood cells are not radiated, it may increase the effectiveness of these white cell transfusions. This may help the white blood cells to make more infection-fighting white blood cells. But, the cells that are also responsible for the transfusion-associated graft versus host disease will not be killed. This increases the risk that you could have this complication. Study Groups: If you agree to take part in this study, and if you are one of the first 40 patients, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You or your physician will not know the results of this randomization. If you are in Group 1, you will have a non-radiated white blood cell transfusion. If you are in Group 2, you will have a standard white blood cell transfusion (with radiation). If you are less than 50 years old, you will receive 4 transfusions of radiated white cells. If you continue to show signs and symptoms of infection you will receive additional white cell transfusions based on the group you were randomized to. If you are after the first 40 patients, you will be placed in a group that the study doctor thinks will most benefit you. It is important to note that this study is designed as a "adaptive randomization" which means that as the outcome for each individual is observed, the next patient receives the product which is most likely to be beneficial and least likely to be harmful. White Blood Cell Transfusion: Before the transfusion, a nurse will take your temperature, breathing rate and blood pressure. During the transfusion a nurse will watch you closely. Side effects sometimes occur during and soon after the transfusion. You may be given a drug to help or reduce any side effects. If you are in Group 2, you will receive 4 standard white blood cell transfusions (with radiation). If you still have an infection after 4 transfusions and the doctor thinks it is necessary, you will have additional transfusions. You will continue to have transfusions until the doctor feels the infection has been controlled. If you experience graft-versus-host disease (GVHD), this will be up to your doctor's discretion. If you need a white blood cell transfusion for a new infection or for an infection that comes back, you will receive the same type of transfusion as you received before. If you were discharged from the hospital and your doctor would like for you to continue receiving white blood cell transfusions, you will be able to receive them as an outpatient. Each transfusion will take from 1 hour to several hours depending on how you tolerate the treatment. Each transfusion will be given daily or as close to daily as possible. Before every infusion, blood (about 1 tablespoon) will be drawn to measure the number of white blood cells in your blood. Length of Study: You will receive transfusions until your doctor feels the infection has been controlled. This is an investigational study. White blood cell transfusions are considered standard procedure for the treatment of serious, life threatening infections. Up to 150 patients will take part in this study. All will be enrolled at The University of Texas (UT) MD Anderson Cancer Center.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
White Blood Cell Transfusion, Radiated Cells, Unradiated Cells, Leukocyte Transfusions, Life-threatening Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
178 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Non-radiated White Blood Cell Transfusion
Arm Type
Experimental
Arm Description
Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
Arm Title
White Blood Cell Transfusion
Arm Type
Experimental
Arm Description
Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
Intervention Type
Procedure
Intervention Name(s)
White Blood Cell Transfusion
Intervention Description
4 Transfusions, each taking approximately 1 hour: Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions. Patients >50 years of age are randomized to receive either radiated or non radiated transfusions.
Primary Outcome Measure Information:
Title
Number of Participants Alive at Day 30
Description
Participant survival measured over the 30 days subsequent to the first granulocyte transfusion. Collecting complete blood counts (CBCs) pre and post transfusion allows determination of whether the duration of neutrophil replacement differs between the two study groups (comparing unradiated white blood cells to radiated white blood cell infusion).
Time Frame
30 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of hematologic malignancy admitted to the Leukemia service. Severe neutropenia defined as Absolute neutrophil count (ANC) less than or equal to 1000. Persistent fever and/or signs of life threatening infection despite 48 hours on antibiotics. Sign a written informed consent form. Greater than 18 years of age. Exclusion Criteria: 1) None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emil J Freireich, MD, BS
Organizational Affiliation
UT MD Anderson Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
UT MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
UT MD Anderson Cancer Center website

Learn more about this trial

A Study for Leukemia Patients With Life-Threatening Infections

We'll reach out to this number within 24 hrs